Scripps Research expands drug repurposing efforts for COVID-19
Scripps Research has pivoted its drug repurposing collection ReFRAME to find antiviral compounds effective against the novel coronavirus. Read More
COVID-19 research consortium expands
The EndPandemic National Data Consortium is about to expand by six life sciences and information technology companies. Read More
Chicago's McCormick Place to house COVID-19 patients
The McCormick Place convention center in Chicago is being converted into an alternate care facility that can house up to 3,000 patients with COVID-19. Read More
NIH tests for SARS-CoV-2 antibodies in the general population
The U.S. National Institutes of Health (NIH) has commenced a study to determine how many adults in the U.S. with no confirmed history of infection with SARS-CoV-2 have antibodies to the virus. Read More
New COVID-19 R&D initiatives announced
A series of new initiatives aims to simplify scientific literature discovery and acquisition during the COVID-19 crisis, according to Research Solutions. These products include the launch of the COVID-19 Research Viewer Gadget. Read More
MilliporeSigma, Jenner Institute partner on COVID-19 vaccine
MilliporeSigma and the Jenner Institute have announced that they are preparing for large-scale manufacturing of the COVID-19 vaccine candidate ChAdOx1 nCoV-19. Read More
Scientists explore SARS-CoV-2 main protease as a drug target
A team of researchers report the structure of the main protease of the novel coronavirus and have identified several drugs that show promise in combating the virus, according to an April 9 article published in Nature. Read More
ThermoGenesis to develop COVID-19 therapeutics
ThermoGenesis has announced that its joint venture, ImmuneCyte Life Sciences, has acquired intellectual property for developing antibody therapeutics for COVID-19. Read More
Eurofins Discovery supports COVID-19 research
Eurofins Discovery has announced that it aims to accelerate COVID-19 antiviral drug discovery research. Read More
New antiviral drug could work against many viruses, including SARS-CoV-2
An antiviral drug called EIDD-2801 that's in preclinical testing has potential to be developed into the silver bullet that medical professionals seek to treat COVID-19, according to new research published in Science Translational Medicine on April 6. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter